Patients with personal or family history of medullary thyroid cancer should not use semaglutide
10.1016/j.atherosclerosis.2012.05.007
These findings reinforce that both are beneficial but with different focus areas: Wegovy for weight reduction and associated risks, Trulicity for blood sugar control and diabetes complications
OSA, hyperlipidemia, CVD) Main exclusion criteria Diabetes HbA1c 6.5% Previous obesity surgery History of chronic pancreatitis Acute pancreatitis within 180 days Baseline characteristics Average age 46 years Female sex - 74% Average weight - 231 lbs (105 kg) Average BMI - 38 Randomized treatment groups Group 1 (1306 patients): Wegovy 2.4 mg subcutaneously once weekly Group 2 (655 patients): Placebo Wegovy was started at a dose of 0.25 mg once weekly and increased every 4 weeks over a period of 16 weeks to a target dose of 2.4 mg once weekly All patients also received diet and exercise counseling Coprimary endpoints were the percentage change in body weight from baseline to week 68 and achievement of a reduction in body weight of 5% or more from baseline to week 68 Primary outcome: Results In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight
If these issues are not addressed, its possible for infections to develop in these areas if proper care is not taken
Zhang JK, Zhang Z, Guo ZA, Fu Y, Chen XJ, Chen WJ, et al
